1.Moriyama T, Tanaka K, Iwasaki C, Oshima Y, Ochi A, Kataoka H, et al. Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan. PLoS One. 2014;9(3):e91756.
2.Lai KN, Tang SC, Schena FP, Novak J, Tomino Y, Fogo AB, et al. IgA nephropathy. Nat Rev Dis Primers. 2016;2:16001.
3.Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, Thibaudin L. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol. 2011;22(4):752–61.
4.Le W, Liang S, Hu Y, Deng K, Bao H, Zeng C, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012;27(4):1479–85.
5.Haas M, Verhave JC, Liu ZH, Alpers CE, Barratt J, Becker JU, et al. A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy. J Am Soc Nephrol. 2017;28(2):691–701.
6.Markowitz G. Glomerular disease: Updated Oxford Classification of IgA nephropathy: a new MEST-C score. Nat Rev Nephrol. 2017;13(7):385–6.
7.Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, et al. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017;91(5):1014–21.
8.Mubarak M. Immunostaining findings in IgA nephropathy: correlation with histology and clinical outcome in the Oxford Classification patient cohort. Nephrol Dial Transplant. 2012;27(7):2998–9; author reply 9–3000.
9.Roberts IS. Pathology of IgA nephropathy. Nat Rev Nephrol. 2014;10(8):445–54.
10.Kim SJ, Koo HM, Lim BJ, Oh HJ, Yoo DE, Shin DH, et al. Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy. PLoS One. 2012;7(7):e40495.
11.Caliskan Y, Ozluk Y, Celik D, Oztop N, Aksoy A, Ucar AS, et al. The Clinical Significance of Uric Acid and Complement Activation in the Progression of IgA Nephropathy. Kidney Blood Press Res. 2016;41(2):148–57.
12.Yoshimura M, Kida H, Abe T, Takeda S, Katagiri M, Hattori N. Significance of IgA deposits on the glomerular capillary walls in IgA nephropathy. Am J Kidney Dis. 1987;9(5):404–9.
13.Ohsawa I, Kusaba G, Ishii M, Sato N, Inoshita H, Onda K, et al. Extraglomerular C3 deposition and metabolic impacts in patients with IgA nephropathy. Nephrol Dial Transplant. 2013;28(7):1856–64.
14.Vignon M, Cohen C, Faguer S, Noel LH, Guilbeau C, Rabant M, et al. The clinicopathologic characteristics of kidney diseases related to monotypic IgA deposits. Kidney Int. 2017;91(3):720–8.
15.Alvarado AS, Andeen NK, Brodsky S, Hinton A, Nadasdy T, Alpers CE, et al. Location of glomerular immune deposits, not codeposition of immunoglobulin G, influences definitive renal outcomes in immunoglobulin A nephropathy. Nephrol Dial Transplant. 2018;33(7):1168–75.
16.Doi T, Kanatsu K, Nagai H, Kohrogi N, Kuwahara T, Hamashima Y. Immunoelectron microscopic studies of IgA nephropathy. Nephron. 1984;36(4):246–51.
17.Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.
18.Zhu X, Li H, Liu Y, You J, Qu Z, Yuan S, et al. Tubular atrophy/interstitial fibrosis scores of Oxford classification combinded with proteinuria level at biopsy provides earlier risk prediction in lgA nephropathy. Sci Rep. 2017;7(1):1100.
19.D’Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000;36(2):227–37.
20.Chen T, Li X, Li Y, Xia E, Qin Y, Liang S, et al. Prediction and Risk Stratification of Kidney Outcomes in IgA Nephropathy. Am J Kidney Dis. 2019.
21.Magistroni R, D’Agati VD, Appel GB, Kiryluk K. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int. 2015;88(5):974–89.
22.Edstrom Halling S, Soderberg MP, Berg UB. Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification). Nephrol Dial Transplant. 2012;27(2):715–22.
23.Shima Y, Nakanishi K, Hama T, Mukaiyama H, Togawa H, Hashimura Y, et al. Validity of the Oxford classification of IgA nephropathy in children. Pediatr Nephrol. 2012;27(5):783–92.
24.Liu D, You J, Liu Y, Tang X, Tan X, Xia M, et al. Serum immunoglobulin G provides early risk prediction in immunoglobulin A nephropathy. Int Immunopharmacol. 2019;66:13–8.
25.Ni Z, Yuan Y, Wang Q, Cao L, Che X, Zhang M, et al. Time-averaged albumin predicts the long-term prognosis of IgA nephropathy patients who achieved remission. J Transl Med. 2014;12:194.
26.Syrjanen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant. 2000;15(1):34–42.
27.Zhao YY, Vaziri ND, Lin RC. Lipidomics: new insight into kidney disease. Adv Clin Chem. 2015;68:153–75.
28.Jennette JC. The immunohistology of IgA nephropathy. Am J Kidney Dis. 1988;12(5):348–52.
29.Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis. 1997;29(6):829–42.
30.Al Hussain T, Hussein MH, Al Mana H, Akhtar M. Pathophysiology of IgA Nephropathy. Adv Anat Pathol. 2017;24(1):56–62.
31.Nasri H, Sajjadieh S, Mardani S, Momeni A, Merikhi A, Madihi Y, et al. Correlation of immunostaining findings with demographic data and variables of Oxford classification in IgA nephropathy. J Nephropathol. 2013;2(3):190–5.
32.Hara M, Yoshida R, Inaba S, Higuchi A, Suzuki Y, Okada T, et al. C3 deposition in IgA nephropathy in children and adolescents. Acta Paediatr Jpn. 1991;33(3):335–44.